Literature DB >> 23981153

Psychiatric comorbidities in ADHD children: an Iranian study among primary school students.

Shahrokh Amiri1, Ali Reza Shafiee-Kandjani, Ali Fakhari, Salman Abdi, Javad Golmirzaei, Zahra Akbari Rafi, Salman Safikhanlo.   

Abstract

BACKGROUND: This study was performed to determine the lifetime prevalence of psychiatric disorders concomitant with attention deficit/hyperactivity disorder (ADHD) among primary school students.
METHODS: One thousand six hundred fifty-eight primary school students (781 females and 877 males) were selected in a cluster random manner in 2010. The first screening was performed by the Conner's teacher rating scale revised and Teacher ADHD rating scale-IV and then the students, in whom the ADHD was diagnosed by a child and adolescent psychiatrist according to DSM-IV-TR, were evaluated by K-SADS-PL semi-structured interview to detect the psychiatric comorbidities.
RESULTS: The prevalence of psychiatric comorbidities in ADHD subjects was 62.5%. Oppositional defiant disorder (29.4%), specific phobia (21.9%), and enuresis (17.5%) were the most common comorbidities. The most common comorbidities in ADHD-IA (inattentive type) (n = 29) were specific phobia (34.5%), oppositional defiant disorder (20.7%), chronic motor tic disorder (17.2%), and enuresis (17.2%). The most common comorbidities in ADHD-HI (hyperactive/impulsive type) (n = 15) were chronic motor tic disorder (33.3%), oppositional defiant disorder (26.7%), and specific phobia (26.7%). The most common comorbidities in ADHD-C (combined type) (n = 116) were oppositional defiant (31.9%), enuresis (19%), and specific phobia (18.1%). The frequency of chronic vocal tic disorder was higher in ADHD-HI compared with ADHD-C (P = 0.01).
CONCLUSION: The results of this study indicated that the frequency of other psychiatric comorbidities in primary school students with ADHD is high that may affect disease course and treatment. Hence, evaluation for other comorbidities in ADHD patients should be considered.

Entities:  

Mesh:

Year:  2013        PMID: 23981153     DOI: 013169/AIM.006

Source DB:  PubMed          Journal:  Arch Iran Med        ISSN: 1029-2977            Impact factor:   1.354


  6 in total

1.  Comorbidity prevalence and treatment outcome in children and adolescents with ADHD.

Authors:  Laura Reale; Beatrice Bartoli; Massimo Cartabia; Michele Zanetti; Maria Antonella Costantino; Maria Paola Canevini; Cristiano Termine; Maurizio Bonati
Journal:  Eur Child Adolesc Psychiatry       Date:  2017-05-19       Impact factor: 4.785

Review 2.  Attention deficit and hyperactivity disorder and nocturnal enuresis co-occurrence in the pediatric population: a systematic review and meta-analysis.

Authors:  Ana Cecília de Sena Oliveira; Bruno da Silva Athanasio; Flávia Cristina de Carvalho Mrad; Monica Maria de Almeida Vasconcelos; Maicon Rodrigues Albuquerque; Débora Marques Miranda; Ana Cristina Simões E Silva
Journal:  Pediatr Nephrol       Date:  2021-05-19       Impact factor: 3.714

3.  Personality profile of parents of children with attention deficit hyperactivity disorder.

Authors:  Hossein Dadashzadeh; Shahrokh Amiri; Ahmad Atapour; Salman Abdi; Mahan Asadian
Journal:  ScientificWorldJournal       Date:  2014-11-26

4.  Knowledge and Attitude of Parents of Children With Attention Deficit Hyperactivity Disorder Towards the Illness.

Authors:  Shahrokh Amiri; Ali Reza Shafiee-Kandjani; Seyed Gholamreza Noorazar; Sina Rahmani Ivrigh; Salman Abdi
Journal:  Iran J Psychiatry Behav Sci       Date:  2016-05-15

5.  Risk Factors of Nocturnal Enuresis in Children with Attention Deficit Hyperactivity Disorder.

Authors:  Habibolah Khazaie; Farshid Eghbali; Houshang Amirian; Mahmoud Reza Moradi; Mohammad Rasoul Ghadami
Journal:  Shanghai Arch Psychiatry       Date:  2018-02-25

6.  Associations Between Psychiatric Disorders and Enuresis in Taiwanese Children: A National Population-Based Study.

Authors:  Hsin-Lin Tsai; Jei-Wen Chang; Mu-Hong Chen; Mei-Jy Jeng; Ling-Yu Yang; Keh-Gong Wu
Journal:  Clin Epidemiol       Date:  2020-02-18       Impact factor: 4.790

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.